-

Bioptimus Appoints Mathilda Strom as Founding Chief Operating Officer

PARIS--(BUSINESS WIRE)--Bioptimus, a leading AI company building the Foundation Model for biology, is thrilled to announce the appointment of Mathilda Strom as its Founding Chief Operating Officer. Mathilda joins Bioptimus with an extensive track record in building pioneering businesses and a reputation as a leader in scaling impactful organizations globally.

With nearly 20 years of experience, Mathilda brings an entrepreneurial spirit and strategic vision to Bioptimus. Most recently, she served as the Chief Commercial Officer at CarbonPool, the world’s first insurance company to settle claims in carbon credits rather than cash.

Mathilda is no stranger to launching transformative companies. She co-founded BIMA, a microinsurance and digital health player in emerging markets. Under her leadership, BIMA expanded to 23 countries, enabling millions of low- and middle-income families to access critical financial and health services via mobile technology. Throughout her tenure, she forged deep-rooted partnerships with major global players, including Telefonica, Orange, Vodafone, Allianz, and Prudential, further cementing her reputation as an influential leader in the industry.

Beyond her executive experience, Mathilda has served on the boards of organizations like the Microinsurance Network and Azuri Technologies, a renewable energy firm working to bring solar solutions to Africa. She has earned recognition as one of the top 50 female entrepreneurs to watch and among the top 10 future women leaders in Sweden.

As Bioptimus’s new Chief Operating Officer, Mathilda Strom will oversee strategic operations, enhance organizational growth, and drive the company’s mission to fuel breakthroughs in biomedicine and beyond. Her proven expertise in building high-impact, purpose-driven ventures positions her to lead Bioptimus through its next phase of innovation and expansion.

David Cahané, Co-Founder of Bioptimus, said: ""We are thrilled to welcome Mathilda to Bioptimus as our Founding Chief Operating Officer. Her visionary leadership and track record in scaling impactful businesses align perfectly with our mission to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond. Mathilda’s expertise and commitment to innovation will be invaluable as we build the Foundation Model for biology to unlock the potential of generative AI in the field. We are excited to have her on board to help shape the future of our company.”

More News From Bioptimus

Owkin Announces International Validation Results of BRCAura: AI-Driven Screening for gBRCA Mutations Directly From Pathology Slides

PARIS--(BUSINESS WIRE)--Owkin shares promising validation results for BRCAura RUO, a clinical-grade research-use-only AI product designed to screen for germline BRCA1/2 mutations (gBRCAm) directly from digitized breast cancer pathology slides. Breast cancer remains the leading cause of cancer-related deaths among women worldwide. Identifying patients with germline BRCA1/2 mutations is essential for guiding targeted treatment decisions, but testing is not always consistently offered to eligible...

Université Paris-Saclay and Owkin: A Unique Alliance to Propel University Medical Research to the Top of the European Rankings Through AI

PARIS--(BUSINESS WIRE)--Université Paris-Saclay and Owkin announce the signing of a memorandum of understanding to explore the potential of K Pro Free - Owkin’s AI co-pilot for biology - for use by Paris-Saclay. K Pro Free will now be available to the entire Université Paris-Saclay community, and in particular teachers, researchers and doctoral students working in the biomedical sciences. The partnership includes workshops, training sessions and events designed to promote the discovery and adop...

Owkin Unveils Europe’s First Pan-European Agentic Infrastructure for Biology at the Franco-German Digital Sovereignty Summit

BERLIN--(BUSINESS WIRE)--At today’s Franco-German Summit on Digital Sovereignty in Berlin, Owkin, together with leading academic partners Gustave Roussy (France) and Charité Comprehensive Cancer Center (Germany), announced a landmark initiative to build the first pan-European agentic infrastructure to make biological data AI-ready, as a key step towards biological super intelligence. The project aims to develop and deploy modern AI methods to support biological research and drug development. An...
Back to Newsroom